Achillion-Logo-150 (4).jpg
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
May 04, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of...
Achillion-Logo-150 (4).jpg
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 02, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion-Logo-150 (4).jpg
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
April 06, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471,...
Achillion-Logo-150 (4).jpg
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
March 21, 2017 16:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent...
Achillion-Logo-150 (4).jpg
Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 09:01 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...